Understanding Erivedge (Vismodegib) for Advanced Basal Cell Carcinoma
Palmetto Specialty Pharm
A dually accredited, 50 state licensed specialty pharmacy singularly focused on improving the patient's health journey.
Understanding Erivedge (Vismodegib) for Advanced Basal Cell Carcinoma
Erivedge (vismodegib) is a prescription medication designed to treat advanced basal cell carcinoma (BCC) in adults. This medication is specifically indicated for cases where BCC has spread to other parts of the body, recurred after surgery, or cannot be managed with surgery or radiation.
Mechanism of Action
Erivedge works by inhibiting the Hedgehog pathway, a critical signaling pathway involved in the growth and proliferation of basal cell carcinoma. By blocking this pathway, Erivedge helps to slow the progression of the cancer.
Administration and Dosage
Erivedge is supplied as 150 mg oral capsules, which should be stored at room temperature. The dosage and administration schedule are personalized, determined by a healthcare provider based on the specific needs of the patient.
Efficacy
Clinical trials have demonstrated the effectiveness of Erivedge in treating advanced BCC. For instance, a study evaluating its long-term use found that:
Patients with locally advanced BCC had a median progression-free survival of 23.2 months.
Patients with metastatic BCC had a median progression-free survival of 13.1 months.
These findings underscore Erivedge's potential to significantly impact the course of advanced BCC.
Side Effects
Like all medications, Erivedge can cause side effects. Common side effects include:
Muscle spasms
Hair loss
Changes in or loss of taste
Decreased appetite and weight loss
Fatigue
Nausea or vomiting
Diarrhea or constipation
Joint pain
Serious side effects may include severe skin reactions, muscle problems, and bone growth issues in children. Patients experiencing any severe side effects should seek medical attention immediately.
Warnings and Precautions
A critical safety consideration with Erivedge is its potential to cause severe birth defects or fetal death. To mitigate these risks:
Female patients must use effective contraception during treatment and for a specified period after their last dose.
Male patients should also use contraception to prevent potential harm to a developing fetus.
Healthcare providers will discuss these precautions in detail with patients before initiating treatment.
Patient Support Programs
Genentech, the manufacturer of Erivedge, offers patient support through its Erivedge Access Solutions program. This program provides assistance with insurance benefits, prior authorizations, and potential financial aid to ensure eligible patients can access the medication they need.
Conclusion
Erivedge represents a significant advancement in the treatment of advanced basal cell carcinoma. By targeting the Hedgehog pathway, it offers a specialized therapy for patients dealing with this potentially disfiguring and life-threatening condition. With the support of healthcare providers and access programs, Erivedge provides hope and options for patients navigating advanced BCC.